Pyrimidine compounds as JAK kinase inhibitors
US11110095B2 · kind B2 · utility
3Cited by
10References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2019 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Oct 24, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.